{"schema_version":"secwatch.filing_event.v1","accession":"0001689375-25-000009","form_type":"8-K","ticker":"TRDA","cik":"0001689375","company_name":"Entrada Therapeutics, Inc.","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.452571+00:00","generated_at":"2026-05-26T02:10:14.274045+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Entrada Q4 net income $1.1M; FDA lifts hold on ENTR-601-44; cash $420M into Q2 2027","bullets":["Q4 net income $1.1M vs loss $9.5M YoY; FY net income $65.6M vs loss $6.7M.","Collaboration revenue $37.4M Q4, $210.8M FY; R&D expenses $33.4M Q4.","Cash $420M as of Dec 31, 2024; runway expected into Q2 2027.","FDA lifted clinical hold on ENTR-601-44; authorized US Phase 1b MAD study for exon 44 DMD.","MHRA authorized UK Phase 1/2 study for ENTR-601-44; regulatory filings for ENTR-601-45 in UK/EU."],"urls":{"canonical":"https://secwatch.observer/filing/0001689375-25-000009","json":"https://secwatch.observer/filing/0001689375-25-000009.json","markdown":"https://secwatch.observer/filing/0001689375-25-000009.md","text":"https://secwatch.observer/filing/0001689375-25-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689375/000168937525000009/0001689375-25-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689375/000168937525000009/trda-20250227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T02:10:14.274045+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}